SCHEMBL3982965

SCHEMBL3982965

CC=CCCC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26014 1.00
SCHEMBL13626153 0.86
SCHEMBL1270703 0.86
SCHEMBL1270704 0.86
SCHEMBL3901539 0.84 FAAH (0.65)
SCHEMBL3901535 0.84 FAAH (0.65)
SCHEMBL17352280 0.82 FAAH (0.69)
SCHEMBL8696497 0.82 FAAH (0.69)
SCHEMBL8696500 0.82 FAAH (0.69)
SCHEMBL17352281 0.82 FAAH (0.69)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018102261-A2 BORONIC DERIVATIVES HYDROXAMATES AS ANTICANCER AGENTS XAVIER UNIVERSITY OF LOUISIANA (US) 2018-06-07 WO claimed
US-5679831-A Process for the preparation of an ester DSM N.V. (NL) 1997-10-21 US claimed
US-20230129262-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 OGLETREE MARTIN (US) 2023-04-27 US disclosed
EP-4125882-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 Ogletree, Martin (US) 2023-02-08 EP disclosed
CN-115666560-A Methods and pharmaceutical compositions for treating thromboxane A2 receptor antagonists of COVID-19 马丁·奥格特树 2023-01-31 CN disclosed
CN-115624549-A Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists 坎伯兰医药品股份有限公司 2023-01-20 CN disclosed
CN-109152767-B Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists 坎伯兰医药品股份有限公司 2022-10-21 CN disclosed
US-20220211674-A1 Thromboxane Receptor Antagonists in AERD/Asthma CUMBERLAND PHARMACEUTICALS INC. (US) 2022-07-07 US disclosed
WO-2020161072-A1 PROCESS FOR MANUFACTURING QUANTUM DOTS UNIVERSITEIT VAN AMSTERDAM (NL) 2020-08-13 WO disclosed
EP-3693439-A1 METHOD FOR MANUFACTURING QUANTUM DOTS Universiteit van Amsterdam (NL) 2020-08-12 EP disclosed
EP-3601228-A1 MICROBIOCIDAL QUINOLINE (THIO)CARBOXAMIDE DERIVATIVES Syngenta Participations AG (CH) 2020-02-05 EP disclosed
WO-2013185928-A1 METHOD FOR THE PREPARATION OF 1-ARYL-1-ALKYL-2-ALKYL-3-DIALKYLAMINOPROPANE COMPOUNDS SIEGFRIED AG (CH) 2013-12-19 WO disclosed
EP-2056798-A2 SORBIC ACID ANALOG CO-CRYSTALS Amgen, Inc (US) 2009-05-13 EP disclosed
WO-2008024437-A2 SORBIC ACID ANALOG CO-CRYSTALS AMGEN INC. (US) 2008-02-28 WO disclosed
US-20080051453-A1 Sorbic acid analog co-crystals AMGEN INC. 2008-02-28 US disclosed
EP-1346377-A1 ELECTRICAL CABLE, PARTICULARLY FOR HIGH VOLTAGE DIRECT CURRENT TRANSMISSION OR DISTRIBUTION, AND INSULATING COMPOSITION PIRELLI S.p.A. (IT) 2003-09-24 EP disclosed
WO-2002052582-A1 ELECTRICAL CABLE, PARTICULARLY FOR HIGH VOLTAGE DIRECT CURRENT TRANSMISSION OR DISTRIBUTION, AND INSULATING COMPOSITION PIRELLI S.P.A. (IT) 2002-07-04 WO disclosed
EP-0662467-B1 Process for the preparation of an ester DSM NV (NL) 1998-05-06 EP disclosed
US-5679831-A Process for the preparation of an ester DSM N.V. (NL) 1997-10-21 US disclosed
EP-0662467-A1 Process for the preparation of an ester DSM N.V. (NL) 1995-07-12 EP disclosed